EP4077328A4 - Dérivés de pyridopyrimidine en tant qu'inhibiteurs de kras - Google Patents

Dérivés de pyridopyrimidine en tant qu'inhibiteurs de kras Download PDF

Info

Publication number
EP4077328A4
EP4077328A4 EP21757315.3A EP21757315A EP4077328A4 EP 4077328 A4 EP4077328 A4 EP 4077328A4 EP 21757315 A EP21757315 A EP 21757315A EP 4077328 A4 EP4077328 A4 EP 4077328A4
Authority
EP
European Patent Office
Prior art keywords
pyridopyrimidine derivatives
kras inhibitors
kras
inhibitors
pyridopyrimidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21757315.3A
Other languages
German (de)
English (en)
Other versions
EP4077328A1 (fr
Inventor
Don Zhang
Jirong Peng
Michael John COSTANZO
Michael Alan Green
Michael Nicholas Greco
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beta Pharma Inc
Original Assignee
Beta Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beta Pharma Inc filed Critical Beta Pharma Inc
Publication of EP4077328A1 publication Critical patent/EP4077328A1/fr
Publication of EP4077328A4 publication Critical patent/EP4077328A4/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP21757315.3A 2020-02-20 2021-02-19 Dérivés de pyridopyrimidine en tant qu'inhibiteurs de kras Pending EP4077328A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062978954P 2020-02-20 2020-02-20
PCT/US2021/018703 WO2021168193A1 (fr) 2020-02-20 2021-02-19 Dérivés de pyridopyrimidine en tant qu'inhibiteurs de kras

Publications (2)

Publication Number Publication Date
EP4077328A1 EP4077328A1 (fr) 2022-10-26
EP4077328A4 true EP4077328A4 (fr) 2023-11-29

Family

ID=77391707

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21757315.3A Pending EP4077328A4 (fr) 2020-02-20 2021-02-19 Dérivés de pyridopyrimidine en tant qu'inhibiteurs de kras

Country Status (6)

Country Link
US (1) US20230099858A1 (fr)
EP (1) EP4077328A4 (fr)
JP (1) JP2023515479A (fr)
CN (1) CN115135650A (fr)
AU (1) AU2021224733A1 (fr)
WO (1) WO2021168193A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217307A1 (fr) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Inhibiteurs de kras g12c
JP2022517222A (ja) 2019-01-10 2022-03-07 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｃ阻害剤
US11453683B1 (en) 2019-08-29 2022-09-27 Mirati Therapeutics, Inc. KRas G12D inhibitors
JP2022548791A (ja) 2019-09-24 2022-11-21 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法
WO2021127429A1 (fr) 2019-12-20 2021-06-24 Mirati Therapeutics, Inc. Inhibiteurs de sos1
EP4208261A1 (fr) 2020-09-03 2023-07-12 Revolution Medicines, Inc. Utilisation d'inhibiteurs de sos1 pour traiter des malignités à mutations de shp2
EP4214209A1 (fr) 2020-09-15 2023-07-26 Revolution Medicines, Inc. Dérivés d'indole servant d'inhibiteurs dans le traitement du cancer
US20230081426A1 (en) * 2020-09-18 2023-03-16 Plexxikon Inc. Compounds and methods for kras modulation and indications therefor
US20230107642A1 (en) 2020-12-18 2023-04-06 Erasca, Inc. Tricyclic pyridones and pyrimidones
WO2022135470A1 (fr) * 2020-12-22 2022-06-30 上海科州药物研发有限公司 Préparation et procédé d'application d'un composé hétérocyclique utilisé en tant qu'inhibiteur de kras
TW202246261A (zh) * 2021-02-11 2022-12-01 大陸商晶銳醫藥（蘇州）有限公司 作為抗癌劑的化合物
TWI810803B (zh) * 2021-03-15 2023-08-01 大陸商藥雅科技（上海）有限公司 突變蛋白抑制劑的製備及其應用
TWI814234B (zh) * 2021-03-15 2023-09-01 大陸商藥雅科技（上海）有限公司 突變蛋白抑制劑的製備及其應用
CN117616031A (zh) 2021-05-05 2024-02-27 锐新医药公司 用于治疗癌症的ras抑制剂
EP4334321A1 (fr) 2021-05-05 2024-03-13 Revolution Medicines, Inc. Inhibiteurs de ras
CN117813306A (zh) * 2021-05-22 2024-04-02 上海科州药物研发有限公司 作为kras抑制剂的杂环化合物，及其制备和治疗用途
WO2022266206A1 (fr) 2021-06-16 2022-12-22 Erasca, Inc. Conjugués d'inhibiteurs de kras
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
AU2022399372A1 (en) * 2021-11-30 2024-05-16 Beta Pharma, Inc. Fused pyrimidine derivatives as kras oncoprotein inhibitors
WO2023114954A1 (fr) 2021-12-17 2023-06-22 Genzyme Corporation Composés pyrazolopyrazine utilisés comme inhibiteurs de la shp2
EP4227307A1 (fr) 2022-02-11 2023-08-16 Genzyme Corporation Composés pyrazolopyrazine en tant qu'inhibiteurs de shp2
WO2023172940A1 (fr) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Méthodes de traitement du cancer du poumon réfractaire immunitaire
WO2023240263A1 (fr) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Inhibiteurs de ras macrocycliques
WO2024006445A1 (fr) * 2022-06-29 2024-01-04 Frontier Medicines Corporation Méthodes de traitement du cancer
WO2024081674A1 (fr) 2022-10-11 2024-04-18 Aadi Bioscience, Inc. Polythérapies pour le traitement du cancer
WO2024102421A2 (fr) 2022-11-09 2024-05-16 Revolution Medicines, Inc. Composés, complexes, et leurs procédés de préparation et d'utilisation
CN116120315B (zh) * 2023-04-19 2023-06-09 山东绿叶制药有限公司 一种kras g12c抑制剂及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020239077A1 (fr) * 2019-05-29 2020-12-03 上海翰森生物医药科技有限公司 Régulateur dérivé hétérocyclique contenant de l'azote, son procédé de préparation et son application
WO2022135470A1 (fr) * 2020-12-22 2022-06-30 上海科州药物研发有限公司 Préparation et procédé d'application d'un composé hétérocyclique utilisé en tant qu'inhibiteur de kras

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032493A1 (en) * 2005-05-26 2007-02-08 Synta Pharmaceuticals Corp. Method for treating B cell regulated autoimmune disorders
AU2017266911B2 (en) * 2016-05-18 2021-09-02 Array Biopharma, Inc. KRas G12C inhibitors
EA202091186A1 (ru) * 2017-11-15 2020-10-01 Мирати Терапьютикс, Инк. ИНГИБИТОРЫ KRas G12C
MA52501A (fr) * 2018-05-04 2021-03-10 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
WO2021139678A1 (fr) * 2020-01-07 2021-07-15 广州百霆医药科技有限公司 Inhibiteur pyridopyrimidine de protéine mutante kras g12c

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020239077A1 (fr) * 2019-05-29 2020-12-03 上海翰森生物医药科技有限公司 Régulateur dérivé hétérocyclique contenant de l'azote, son procédé de préparation et son application
EP3978490A1 (fr) * 2019-05-29 2022-04-06 Shanghai Hansoh Biomedical Co., Ltd. Régulateur dérivé hétérocyclique contenant de l'azote, son procédé de préparation et son application
WO2022135470A1 (fr) * 2020-12-22 2022-06-30 上海科州药物研发有限公司 Préparation et procédé d'application d'un composé hétérocyclique utilisé en tant qu'inhibiteur de kras

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2021168193A1 *

Also Published As

Publication number Publication date
US20230099858A1 (en) 2023-03-30
CN115135650A (zh) 2022-09-30
WO2021168193A1 (fr) 2021-08-26
AU2021224733A1 (en) 2022-09-01
JP2023515479A (ja) 2023-04-13
EP4077328A1 (fr) 2022-10-26

Similar Documents

Publication Publication Date Title
EP4077328A4 (fr) Dérivés de pyridopyrimidine en tant qu'inhibiteurs de kras
EP3741756A4 (fr) Dérivé de pyridone-pyrimidine agissant en tant qu'inhibiteur de mutéine krasg12c
WO2012030685A3 (fr) Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
EP3774812A4 (fr) Composés macrocycliques en tant qu'inhibiteurs de kinases trk
EP3978503A4 (fr) 9-HYDROXY-1,8-DIOXO-1,3,4, 8-TETRAHYDRO-2H-PYRIDO[1,2-a] PYRAZINE-7-CARBOXAMIDES ANNELÉS CONSISTANT EN DES INHIBITEURS D'INTÉGRASE DU VIH
IL310403A (en) Converted pyridine derivatives as SARM1 inhibitors
EP4003993A4 (fr) Dérivés 2-morpholinopyridine substitués utilisés en tant qu'inhibiteurs de kinases atr
EP3982949A4 (fr) Inhibiteurs de sarm1
EP3980011A4 (fr) Inhibiteurs de sarm1
EP4043450A4 (fr) Dérivés 2h-benzopyrane utilisables en tant qu'inhibiteurs de crac
IL292182A (en) History of [4,1]oxazepino[3,2-c]quinolinone as bcl6 inhibitors
EP3962897A4 (fr) Pyrrolopyridines substituées en tant qu'inhibiteurs de jak
EP4137484A4 (fr) Composés tricycliques servant d'inhibiteurs d'egfr
EP3781574A4 (fr) Spiroéthers macrocycliques utilisés en tant qu'inhibiteurs de mcl-1
EP3939588A4 (fr) Utilisations d'inhibiteurs de la phosphodiestérase
EP3907225A4 (fr) Composés dérivés d'imidazopyridine et leur utilisation
EP3941525A4 (fr) Dérivés de benzodiazépine en tant qu'inhibiteurs de rsv
EP3946288A4 (fr) Dérivés de 5-cyclopropyl-1h-pyrazol-3-yl-amine substitués utilisés en tant qu'inhibiteurs sélectifs de cdk12/13
EP3844166A4 (fr) Macrocycles substitués utiles en tant qu'inhibiteurs de kinase
AU2021314940A1 (en) Use of piperdine-1-carbodithioic acid-3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-ylmethyl ester
IL299175A (en) Tetrazole history as TRPA1 inhibitors
EP3858834A4 (fr) Dérivé de pyrazolopyrimidine en tant qu'inhibiteur de trk sélectif
EP3908319A4 (fr) Composés inhibiteurs de métalloenzyme
EP3758698A4 (fr) Dérivés éthanediamine-hétérocycle utilisés en tant qu'inhibiteurs des protéine arginine méthyltransférases
EP3712157A4 (fr) Composés de pyridopyrimidine agissant en tant qu'inhibiteurs de la double kinase mtorc 1/2

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220722

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230601

A4 Supplementary search report drawn up and despatched

Effective date: 20231027

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/519 20060101ALI20231023BHEP

Ipc: A61P 35/00 20060101ALI20231023BHEP

Ipc: C07F 9/6561 20060101ALI20231023BHEP

Ipc: C07D 519/00 20060101ALI20231023BHEP

Ipc: C07D 471/04 20060101AFI20231023BHEP